Abbott Laboratories: Reasonably Valued After Surge, But Still An Attractive Buy Long-TermSeeking Alpha • 08/19/26
Abbott and NACHC launch nationwide Food for Health initiative to make nutritious food a core part of healthcarePRNewsWire • 08/17/26
What's Backing Abbott's Established Pharmaceuticals Division GrowthZacks Investment Research • 08/13/26
Abbott and Google launch first-of-its-kind partnership to transform everyday health through glucose insights and AIPRNewsWire • 08/11/26
Should You Buy, Hold or Sell ABT Stock Amid Medical Devices Boom?Zacks Investment Research • 08/10/26
AbbVie vs. Abbott Laboratories: Which Healthcare Stock Is a Better Buy in 2026?The Motley Fool • 08/07/26
Here's How ABT Broadens Diagnostics Growth Base With Oncology ExpansionZacks Investment Research • 08/07/26
Abbott Laboratories Lost 16% This Year: One Analyst Sees 35% Gains for the Healthcare Giant24/7 Wall Street • 08/03/26
Abbott Laboratories vs. Eli Lilly: Which Healthcare Stock Is a Better Buy in 2026?The Motley Fool • 08/02/26
Abbott Laboratories vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026?The Motley Fool • 07/31/26
Abbott Rides Key Diabetes, Oncology and Heart Care Innovation TrendsZacks Investment Research • 07/28/26
Is Abbott Stock Attractive After Its Earnings and Guidance Update?Zacks Investment Research • 07/27/26
FDA Approves Freenome's SimpleScreen™ CRC Blood-Based Screening Test; Abbott to Commercialize in the U.S.GlobeNewsWire • 07/27/26
Johnson & Johnson vs Abbott Laboratories: Two Healthcare Giants on Opposite Trajectories24/7 Wall Street • 07/21/26